A French biotech focused on developing genetic medicines for neurological conditions has secured €27 million in a Series B ...

Zealand Pharma reports 2024 results but no partnering deal for petrelintide. CEO Adam Steensberg remains confident despite ...

Hims & Hers bought an at-home lab test­ing com­pa­ny as it branch­es out in­to oth­er clin­i­cal ar­eas be­yond its re­cent ...

Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on ...

Ascletis Pharma's oral GLP-1 drug ASC30 shows 6.2% placebo-adjusted weight loss in Phase 1b obesity trial, matching Roche's ...

Gen­uine Biotech files for HKEX list­ing: The drug de­vel­op­er, which has mul­ti­ple lo­ca­tions in Chi­na, Get free access to a limited number of articles, plus choose newsletters to get straight to ...

On a sunny September day in 2023, scientists at CRISPR Therapeutics invited me to peer through their microscopes. Through the ...

FDA blocks Tyche Industries & Jagsonpal Pharmaceuticals from shipping products after inspections found GMP violations in ...

Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called ...

Supernus Pharmaceuticals' depression drug SPN-820 fails Phase 2b trial due to high placebo response, causing 20% stock drop.

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe ...

Spot­light Ther­a­peu­tics, a start­up with a bold vi­sion for de­liv­er­ing CRISPR ther­a­pies in­to the body with­out the ...